Proteome Sciences (PMSNF)

Monday

7:32 AM

ThesisRecent strategic partnerships and advancements in clinical trials are expected to enhance revenue potential and market position.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$4M	$4M	$4M
Rev. Growth	-23.1%	+15.3%	-11.7%
EPS	$-0.01	$-0.01	$-0.01
EPS Growth	+9.6%	+35.0%	-31.8%
P/E	—	—	—

★ Analysts see FY2026 revenue reaching $4M — +15.3% growth in a single year.

Why Revenue Could Accelerate

01Recent partnership with a leading pharmaceutical company for Alzheimer's biomarker testing could increase revenue by 25% over the next year.
02Successful completion of Phase II clinical trials for a new cancer diagnostic test, potentially leading to regulatory approval by Q4 2026.
03Increased demand for personalized medicine driving higher adoption rates of proteomic tests, with a projected growth rate of 15% annually.
04Personalized medicine and targeted therapies
05Advancements in proteomics technology
06Advancements in biomarker discovery for Alzheimer's and cancer
07Partnerships with pharmaceutical companies for drug development
08Regulatory approvals for new diagnostic tests

FY2025 Snapshot

Revenue: $4M
Rev. Growth: -23.1%
Gross Margin: -26.8%
Op. Margin: -69.9%
Net Margin: -81.5%
Net Income: $-3M
NI Growth: +10.1%
EPS: $-0.01
1Y Return: -75.0%

My Notes

"Our innovative approach to biomarker discovery is gaining traction in the market, positioning us for significant growth."
Moat: Proteome Sciences has a moderate moat due to its proprietary technologies and specialized knowledge in proteomics.
growth - Investors looking for companies with innovative technologies and high potential for market expansion.
Interest rates affect the company's cost of capital for funding research and development, which could impact growth initiatives.
Watch on earnings: Revenue from diagnostic testing services, Number of patents filed related to proteomic technologies, Clinical trial success rates.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $4M to $4M as recent partnership with a leading pharmaceutical company for alzheimer's biomarker testing could increase revenue by 25%.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.